Background/Aims: Inflammatory bowel disease (IBD) is accompanied by lesions in the
Introduction
Inflammatory bowel disease (IBD), with its two main sub-forms ulcerative colitis (UC) and Crohn's disease (CD), is an important health problem with worldwide increasing prevalence 1, 2 . IBD is characterized by chronic and relapsing intestinal inflammation and affected patients suffer from significant clinical symptoms such as abdominal pain, diarrhoea or fever 3 . Extraintestinal manifestations such as inflammation of the skin, joints, liver or the eyes are common complications 4, 5 . Though the exact pathophysiology is still unknown, it is evident that genetic factors, environmental triggers, and aberrant immune responses towards the commensal microbiota contribute to the development of IBD 2, [5] [6] [7] .
The human intestine is populated by up to 10 13 microbes, which form a complex ecosystem 8, 9 . While these microbes are usually harmless or even beneficial to the host 10 , some microbial products, including the bacterial cell wall component lipopolysaccharide (LPS), can promote immune responses and thereby contribute to the development, progression, and exacerbation of IBD 11 . To prevent translocation of pro-inflammatory products from the gut lumen to the systemic circulation, where they elicit strong immune reactions, an adequate protective immunity towards invading bacteria is crucial. This includes a tight epithelial barrier, as well as rapid clearance of bacterial products and invading pathogens by innate immune cells located directly beneath the epithelial layer 9, 12 . In addition, the production of immunoglobulins (Ig) against bacterial products prevents those molecules to pass the epithelial surface 13, 14 . Further, IgA seems to be involved in determining the composition of the intestinal microbiome 13, 14 , which is also a crucial factor for intestinal health 8 . In IBD, these first line defence mechanisms are disturbed, and increased levels of bacterial products, including LPS are detected in the serum [15] [16] [17] . LPS triggers the activation of toll-like receptor (TLR)4 on host cells, resulting in production of IL-6, tumour necrosis factor (TNF), Colostrum is the milk produced by lactating mammals within the first 72 h after giving birth.
In comparison to normal milk, colostrum contains high levels of immune-active molecules, such as IgA/IgG, growth factors, anti-microbial agents (e.g. lysozyme and lactoperoxidase), as well as lactoferrin and vitamins [18] [19] [20] . In contrast to human colostrum, which is rich in IgA, the main immunoglobulin found in bovine colostrum is IgG. This is of interest, since IgA can pass mucosal surfaces via the IgA transporter and possibly translocate to the systemic circulation, while IgG remains in the intestinal lumen. IMM-124E is a bovine colostrumbased product obtained from cows that have been immunized with LPS from Escherichia coli, which results in high levels of LPS-specific IgG. A study investigating the composition of IMM-124E has been published recently, showing that 1mg IMM-124E powder contains about 0.4mg total IgG, which is comparable to the total IgG content in colostrum powder 21 . In previous studies, it has been demonstrated that administration of IMM-124E ameliorates disease in a model of non-alcoholic steatohepatitis (NASH) 22, 23 , a disease where chronic presence of LPS and subsequent low-grade inflammation might promote disease activity 24, 25 .
Further, in TNBS-induced colitis, IMM-124E treatment resulted in reduced colitis severity and promoted the development of CD4 + CD25 + regulatory T cells 26 , but its effect on barrierdisruption-mediated colitis has not been addressed so far. In addition, IMM-124E treatment fostered the development of CD25 high regulatory T helper and regulatory NKT cells in a mouse model of NASH 22 , indicating that IMM-124E might have potent immune cell modulatory effects.
Here, we further investigated the anti-inflammatory potential of IMM-124E in two mouse models of colitis, namely the dextran sodium sulphate (DSS) model of acute barrier A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t at an appropriate concentration in autoclaved water directly prior to administration via oral gavage. The following treatment groups were used in DSS colitis: preventive treatment: 100 mg/kg body weight or 500 mg/kg IMM-124E per day, starting two days before beginning of DSS application (day 2 of the experiment). Administration of 100 mg/kg colostrum from nonimmunized cows served as a treatment control. Therapeutic treatment: 500 mg/kg IMM-124E
per day, starting at day three of the DSS treatment. In transfer colitis, the following treatment groups were studied: 25 mg/kg, 100 mg/kg, or 500 mg/kg IMM-124E once per day.
Administration of 100 mg/kg BSA or transfer of regulatory T cells served as controls. A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t
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Results

Administration of IMM-124E prevents acute DSS-induced colitis.
To test whether administration of IMM-124E is able to ameliorate colitis in vivo, we induced acute colitis in WT C57Bl/6J mice via administration of 2.5% DSS in the drinking water for 7
days. This treatment resulted in severe intestinal inflammation, characterized by diarrhoea, severe weight loss ( Figure 1A ), macroscopic signs of colitis in endoscopy accompanied by elevated MEICS score (colon wall thickening, disturbed vascularization pattern, granular appearance of the colon wall, fibrin deposits, and loose stool, Figure 1B+C ), shortening of the colon ( Figure 1D ), increased levels of myeloperoxidase in colon tissue ( Figure 1E ), and histological signs of severe colitis (erosion of the epithelium, infiltration of immune cells, edema in the sub-epithelium; figure 1F-I).
To test whether IMM-124E prevents colitis development, mice were treated with 100 mg/kg body weight or 500 mg/kg IMM-124E per day, starting two days before beginning of DSS application (preventive treatment). Administration of 100 mg/kg colostrum from nonimmunized cows served as a treatment control. Another group received 500 mg/kg IMM-124E in a therapeutic setting, starting the gavages at day three of the DSS treatment. Of interest, all treatment schedules resulted in less severe weight loss in comparison to DSS only ( Figure 1A ), while colon length was not changed in any of the treatment groups ( Figure 1D ).
However, other indicators of colitis severity showed clear differences between the treatment groups: for instance, MPO levels were only reduced in mice treated with 100 mg/kg IMM-124E, while 500 mg/kg IMM-124E (preventive or therapeutic) and colostrum administration did not affect MPO activity ( Figure 1E ). Preventive treatment with IMM-124E (100 mg/kg and 500 mg/kg) or with colostrum resulted in less severe colitis, as observed in mouse endoscopy, while therapeutic treatment did not significantly reduce macroscopic signs of colitis ( Figure 1B+C ). Preventive 100 mg/kg IMM-124E treatment had the most pronounced effect, which was most overt in reduced levels of disturbed vascularization and granularity of with 100 mg/kg colostrum had no effect on the secretion of these cytokines ( Figure 2E , G+H). IL-10 levels were not significantly affected by any of the treatments ( Figure 2F ). 
IMM-124E ameliorates T cell mediated colitis.
IMM-124E affects immune cells in the inflamed colon.
It has previously been shown that IMM-124E treatment results in enhanced levels of propria and mLN of mice treated with 100 mg/kg IMM-124E ( Figure 4D ). While 25 mg/kg and 500 mg/kg IMM-124E treatment had some effect on Th cell subsets, this was clearly less pronounced. On the other hand, numbers of NK1.1 + NK cells were very low and no significant effects were observed upon colitis induction or IMM-124E treatment ( Figure 4E ).
Of note, all the beneficial effects observed upon IMM-124E treatment were absent in the control group receiving BSA.
IMM-124E prevents systemic LPS exposure upon colitis induction.
IMM-124E contains high levels of anti-LPS IgG, and might therefore neutralize LPS translocation from the gut lumen into the systemic circulation. Although LPS itself is typically below detection limits, systemic exposure to LPS results in expression of LPSbinding protein (LBP), and LBP levels correlate with the extent of LPS exposure. Therefore, we next addressed whether LBP levels are increased in DSS colitis, and whether IMM-124E administration might affect LBP levels in the serum of DSS treated mice. In line with a severe barrier defect, DSS-treatment resulted in significantly enhanced serum levels of LBP ( Figure   5A ). IMM-124E administration significantly reduced serum levels of LBP. However, and in contrast to a better response to 100 mg/kg IMM-124E with respect to colitis indicators, this effect was not dose-dependent, i.e. 500 mg/kg IMM-124E administration was as effective as 100 mg/kg, while administration of colostrum did not affect serum LBP levels ( Figure 5A ).
Nevertheless, levels of LBP moderately correlated with histological scores (Figure 5B ), indicating that systemic LPS translocation might be involved in mediating disease in DSSinduced colitis. LBP serum levels were also increased in T cell transfer colitis ( Figure 5C ), however to a lesser extent than in the DSS model. Again, IMM-124E administration reduced LBP levels in the serum, but there was only a weak correlation between LBP levels and total histology scores ( Figure 5D ). To investigate whether there is direct presence of LPS in the mouse serum after colitis induction, we next used HEKble-mTLR4 cells. These cells carry a To further investigate whether IMM-124E treatment reduces LPS-induced signalling cascades in DSS-treated mice, we analysed activation of NF-B in colon lysates from mice with acute colitis with or without IMM-124E treatment. We saw a strong induction of NF-B p65 phosphorylation in DSS-treated mice, which was clearly suppressed upon treatment with IMM-124E ( Figure 5F ). To address whether IMM-124E treatment also results in reduced translocation of whole bacteria, we measured levels of bacterial 16S rDNA in mesenteric lymph nodes from our mice. However, we only observed 16S rDNA in very few mice, and did not observe any clear pattern (data not shown). Taken together, these data indicate that IMM-124E-treatment prevents DSS-induced systemic exposure to LPS and LPS-induced proinflammatory signalling.
Therapeutic potential of IMM-124E is partially dependent on presence of IgG.
To further investigate the mechanism of action of IMM-124E, we next performed an acute DSS colitis experiment using either the normal IMM-124E preparation, or IgG-depleted IMM-124E. In line with our findings that IMM-124E-treatment reduces exposure to LPS, which is likely due to high levels of anti-LPS antibody load, IgG depletion from IMM-124E
partially abrogated the beneficial effect of IMM-124E ( Figure 6 ). Of interest, the most effective dose of IMM-124E administration was 100mg/kg, which was even more effective than higher doses of IMM-124. Since the exact mechanism how Imm-124E works is still elusive, it is hard to tell why this might be the case. One possible explanation could be that high doses of IMM-124E might result in the formation of immune complexes of IgG with LPS, which could activate antigen-presenting cells in the intestine and thus promote pro-inflammatory effects. On the other hand, IMM-124E is a cow milk based product. Adult mice do not usually ingest milk and in combination with a barrier defect exposure to high levels of milk proteins might contribute to disease symptoms and thus suppress the beneficial effect of IMM-124E. However, further experiments would be required to understand the exact mechanism why IMM-124E is most effective at 100mg/kg.
A recent study that investigated how IMM-124E might exert its anti-diarrheagenic effects, demonstrated that IMM-124E has direct anti-bacterial activity via inhibition of growth and migration of bacteria 21 . This indicates that also during colitis, the beneficial effect of IMM-124E is possibly due to direct anti-bacterial properties, which might lead to decreased In colitis, altered cytokine responses significantly contribute to disease development and exacerbation 32 . IL-10 is one of the most important anti-inflammatory cytokines for the maintenance of intestinal health [33] [34] [35] , and defects in the IL-10 signalling pathway predisposes to very early onset of IBD 36, 37 . While Ya'acov et al found increased levels of IL-10 in the serum of TNBS treated mice that received IMM-124E 26 , we found that IMM-124E prevented DSS-induced induction of IL10 mRNA expression, and there was no significant effect on IL-10 secretion. This indicates that in the DSS model, the effect of IMM-124E does not seem to be mediated via effects on the regulatory cytokine IL-10. In NASH patients treated with be explained by the fact that NK cells exert different effects depending on the disease context 44 . In experimental models of NASH, injection of NK cells alleviated disease via regulation of macrophage activation 45, 46 , while studies of NK cell numbers in IBD have yielded conflicting results 47, 48 .
A c c e p t e d M a n u s c r i p t . In line with decreased levels of infiltrating immune cells into the inflamed colon of IMM-124E treated mice, MPO levels were also significantly decreased, indicating that in addition to prevent aberrant induction of Th cells, IMM-124E also prevents the accumulation of activated myeloid cells.
Summarized, our results demonstrate that IMM-124E administration significantly ameliorates experimental colitis and might be a promising novel therapeutic agent in IBD, either as a stand-alone treatment for maintaining remission in mild colitis cases or in combination with other treatments to increase therapeutic efficacy and prevent loss of therapeutic response. 
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